Pulmonary Arterial Hypertension - A Pipeline Analysis Report

Overview of the drug development pipeline for pulmonary arterial hypertension

PAH, a specific type of pulmonary hypertension, occurs due to scarred tissue in small pulmonary arteries that reduces the diameter of the arteries and results in high blood pressure in lungs. With the accumulation of scarred tissue, the right side of the heart needs to pump blood faster and will overwork. This overworking of the heart may be consequent in heart failure. According to report, almost 44.9% of patients in the UK underwent treatment for PAH in several pulmonary hypertension centers. Technavio’s market research analysts have predicted that with the introduction and development of strategies such as IPAH and APAH to treat pulmonary arterial hypertension, the global pulmonary arterial hypertension market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that significant amount of drug molecules are under the phase I/II and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I stage and several discontinued molecules.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of PAH. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• ACCELERON PHARMA
• ARENA PHARMACEUTICALS
• GALECTIN THERAPEUTICS
• GLAXOSMITHKLINE

Therapeutic assessment of the drug development pipeline for pulmonary arterial hypertension by route of administration

• Oral
• Intravenous (IV)
• Subcutaneous
• Inhalation
• IV+subcutaneous
• Transdermal

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration

Therapeutic assessment of the drug development pipeline for pulmonary arterial hypertension by therapeutic modalities

• Small molecule
• Biological
• Recombinant fusion protein
• Monoclonal antibody

According to this pipeline analysis report, majority of the molecules in the drug development pipeline for pulmonary arterial hypertension are being developed as small molecules. These molecules are chemically manufactured active substances that bind with specific biological macromolecules and act as an effector and alter the activity of the target cell. The low molecular weight of these molecules enables them to enter the body easily.

Technavio also offers customization on reports based on specific client requirement.